Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Signal Transduction Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LYPLA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LYPLA2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. |
View LYPLA2 Products |
| Gene Delivery | LYPLA2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View LYPLA2 Products |
| Benchmark Ab | Anti-LYPLA2 Recombinant Antibody Recombinant positive control for assay validation. |
View LYPLA2 Products |
| Validator | LYPLA2 siRNA Set For target knockdown and specificity verification. |
View LYPLA2 Products |
| Related Target A | LYPLA1 (APT1) Homologous acyl-protein thioesterase; critical for selectivity counter-screening. |
View LYPLA1 Products |
| Related Target B | KRAS Downstream oncogene regulated by palmitoylation/depalmitoylation cycles. |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against LYPLA1 (APT1) | Human LYPLA1 and LYPLA2 ortholog proteins strictly verified by mass spectrometry to guarantee identity and minimize cross-reactivity. |
| High-Throughput Screening (HTS) Compatibility | High-purity recombinant proteins (>95% by SDS-PAGE) with low endotoxin levels, optimized for fluorogenic substrate assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated siRNA sets included in the catalog. |
| False Positives in Cellular Assays | Validated siRNA available for target-specific knockdown verification in cellular depalmitoylation assays. |
Live LYPLA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LYPLA2 (also known as APT2) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum enzyme inhibitors to highly selective small-molecule modulators. As first-generation depalmitoylation inhibitors reach preclinical and early clinical evaluation, the next wave of R&D is targeting the dynamic regulation of oncogenic proteins like RAS family members. Resolving the structural and functional selectivity between LYPLA1 and LYPLA2 remains the pivotal hurdle in developing safe, non-toxic therapeutic candidates.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | KRAS-driven Cancers, Melanoma | Selectivity Assay (Requires highly pure LYPLA1 and LYPLA2 proteins for counter-screening) |
| Targeted Protein Degraders (PROTACs) | Oncology-focused Biopharmas | Refractory Solid Tumors | Ubiquitination & Degradation Validation (Requires Lentivirus for stable cell line expression) |